{"id":60894,"date":"2024-02-28T07:13:40","date_gmt":"2024-02-28T07:13:40","guid":{"rendered":"https:\/\/medsname.com\/hertraz-injection\/"},"modified":"2026-04-30T14:45:56","modified_gmt":"2026-04-30T14:45:56","slug":"hertraz-injection","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/hertraz-injection\/","title":{"rendered":"Hertraz Injection"},"content":{"rendered":"
\n

Snelle antwoord<\/h3>\n

Hertraz Injection<\/strong> is een specialistisch gecontroleerd oncologiemiddel \u2014 toegediend onder ziekenhuisbegeleiding. Lees de doserings-, bijwerkingen- en interactiesecties hieronder voor gebruik; de FAQ's onderaan behandelen de meest voorkomende vragen.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n

Productoverzicht<\/strong><\/p>\n

Hertraz Injection is a medication containing the active ingredient Trastuzumab, available in vial form with a concentration of 440mg per vial. Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer, including breast cancer and gastric cancer. It is a targeted therapy that works by binding to specific receptors on cancer cells, inhibiting their growth and promoting cell death. Hertraz Injection is administered intravenously under the supervision of a healthcare professional.<\/p>\n

Toepassingen<\/strong><\/p>\n

Hertraz Injection is indicated for the treatment of HER2-positive breast cancer, either alone or in combination with other chemotherapy agents. It is also used in combination with other drugs to treat HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers overexpress the human epidermal growth factor receptor 2 (HER2), and Trastuzumab specifically targets these receptors to inhibit cancer cell proliferation.<\/p>\n

Hoe te gebruiken<\/strong><\/p>\n

Hertraz Injection is administered as an intravenous infusion by a healthcare provider in a clinical setting. The dosage and infusion rate are determined based on the patient’s body weight and medical condition. Prior to administration, the vial should be inspected visually for any particulate matter or discoloration. The injection should be given over a specified period, and patients are monitored for any signs of infusion-related reactions during and after the infusion.<\/p>\n

Werking<\/strong><\/p>\n

Trastuzumab, the active ingredient in Hertraz Injection, is a monoclonal antibody that targets and binds to the HER2 receptors present on the surface of cancer cells. By binding to these receptors, Trastuzumab inhibits downstream signaling pathways that promote cell proliferation and survival. Additionally, it can stimulate the immune system to attack HER2-positive cancer cells, further enhancing its anticancer effects. This targeted approach helps to selectively destroy cancer cells while minimizing damage to healthy tissues.<\/p>\n

Dosering en toediening<\/strong><\/p>\n

The recommended dosage of Hertraz Injection varies depending on the type and stage of cancer being treated, as well as other factors such as the patient’s weight and overall health. It is typically administered intravenously every 1 to 3 weeks, with the dosage adjusted based on the patient’s tolerance and response to treatment. Treatment duration may vary, and patients should follow the dosing schedule recommended by their healthcare provider.<\/p>\n

Voordelen<\/strong><\/p>\n